2024 AAD Annual Meeting: Samsung Bioepis presents final 52-week Phase 3 results for SB17 biosimilar to Stelara, and FDA approves SB5 (HADLIMA)
Samsung Bioepis presented two new study results at the 2024 American Academy of Dermatology (AAD) Annual Meeting for its immunology portfolio. SB5, a biosimilar to Humira, was approved by the FDA as HADLIMA and is being reviewed for interchangeability. The final 52-week results from the Phase 3 study for SB17, a proposed biosimilar to Stelara, demonstrated comparable long-term efficacy, safety, and immunogenicity to reference ustekinumab.
March 09, 2024
4 Articles